Osteoarthritis Pipeline and Clinical Trials Assessment 2023: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Bayer AG, OrthogenRx, Abbott Laboratories, Glaxosmithkline plc, Sanofi SA, Pfizer Inc., Zimmer Biomet

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Osteoarthritis pipeline constitutes 130+ key companies continuously working towards developing 130+ Osteoarthritis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Osteoarthritis Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Osteoarthritis Market.

The Osteoarthritis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Osteoarthritis Pipeline Report: https://www.delveinsight.com/sample-request/osteoarthritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Osteoarthritis treatment therapies with a considerable amount of success over the years.
• Osteoarthritis companies working in the treatment market are Ribomic, BRIM Biotechnology, Peptinov, 4movingbiotech, Eupraxia Pharmaceuticals, Ensol Biosciences Inc., Bone Therapeutics, Cynata Therapeutics, Biosplice Therapeutics, and others, are developing therapies for the Osteoarthritis treatment
• Emerging Osteoarthritis therapies in the different phases of clinical trials are- RBM-010, BRM521, PPV-06, 4P-004, EP-104, Engedi1000, JTA-004, CYP 004, Lorecivivint, and others are expected to have a significant impact on the Osteoarthritis market in the coming years.
• In September 2021, The licencing agreement between Biosplice Therapeutics and Haisco Pharmaceutical Group Co., Ltd. was recently signed, and it gives Haisco the exclusive right to produce and market lorecivivint (SM04690) in China for the treatment of knee osteoarthritis ("OA") and other musculoskeletal diseases
• In April 2021, Samil Pharmaceutical Co. Ltd. and Biosplice Therapeutics, Inc. announced the signing of a licencing agreement that gives Samil the exclusive right to develop and market lorecivivint (SM04690) in the Republic of Korea for the treatment of knee osteoarthritis ("OA")
• In August 2020, A long-term extension study was started by Biosplice Therapeutics to assess the effectiveness and safety of Lorecivivint in people with knee osteoarthritis. A long-term extension to the Phase III parent-study SM04690-OA-11 is intended by this study

Osteoarthritis Overview
The most typical type of arthritis is osteoarthritis (OA). Some people refer to it as "wear and tear" arthritis or degenerative joint disease. It usually affects the hands, hips, and knees. A joint's cartilage starts to degrade and the underlying bone starts to change as a result of OA.

Get a Free Sample PDF Report to know more about Osteoarthritis Pipeline Therapeutic Assessment- https://www.delveinsight.com/report-store/osteoarthritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Osteoarthritis Drugs Under Different Phases of Clinical Development Include:
• RBM-010: Ribomic
• BRM521: BRIM Biotechnology
• PPV-06: Peptinov
• 4P-004: 4movingbiotech
• EP-104: Eupraxia Pharmaceuticals
• Engedi1000: Ensol Biosciences Inc.
• SMUP-IA-01: Medipost
• TTAX03: Tissue Tech
• JTA-004: Bone Therapeutics
• CYP 004: Cynata Therapeutics
• Lorecivivint: Biosplice Therapeutics

Osteoarthritis Route of Administration
Osteoarthritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Intravenous
• Subcutaneous

Osteoarthritis Molecule Type
Osteoarthritis Products have been categorized under various Molecule types, such as
• Small molecule
• Cell Therapy
• Peptides
• Polymer
• Small molecule
• Gene therapy

Osteoarthritis Pipeline Therapeutics Assessment
• Osteoarthritis Assessment by Product Type
• Osteoarthritis By Stage and Product Type
• Osteoarthritis Assessment by Route of Administration
• Osteoarthritis By Stage and Route of Administration
• Osteoarthritis Assessment by Molecule Type
• Osteoarthritis by Stage and Molecule Type
DelveInsight's Osteoarthritis Report covers around 130+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Osteoarthritis product details are provided in the report. Download the Osteoarthritis pipeline report to learn more about the emerging Osteoarthritis therapies at:
https://www.delveinsight.com/sample-request/osteoarthritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Osteoarthritis Therapeutics Market include:
Key companies developing therapies for Osteoarthritis are - Bayer AG, OrthogenRx, Abbott Laboratories, Glaxosmithkline plc, Sanofi SA, Pfizer Inc., Zimmer Biomet, Anika Therapeutics Inc., Viatris, Novartis AG, SEIKAGAKU CORPORATION, Assertio Holdings Inc., and others.

Osteoarthritis Pipeline Analysis:
The Osteoarthritis pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Osteoarthritis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Osteoarthritis Treatment.
• Osteoarthritis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Osteoarthritis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Osteoarthritis market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Osteoarthritis drugs and therapies-
https://www.delveinsight.com/sample-request/osteoarthritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Osteoarthritis Pipeline Market Drivers
• Increase in prevalence of Osteoarthritis, rising geriatric population are some of the important factors that are fueling the Osteoarthritis Market.

Osteoarthritis Pipeline Market Barriers
• However, risk of adverse cardiovascular events associated with the use of NSAIDs in osteoarthritis treatment, high cost associated with the treatment and other factors are creating obstacles in the Osteoarthritis Market growth.

Scope of Osteoarthritis Pipeline Drug Insight
• Coverage: Global
• Key Osteoarthritis Companies: Ribomic, BRIM Biotechnology, Peptinov, 4movingbiotech, Eupraxia Pharmaceuticals, Ensol Biosciences Inc., Bone Therapeutics, Cynata Therapeutics, Biosplice Therapeutics, and others
• Key Osteoarthritis Therapies: RBM-010, BRM521, PPV-06, 4P-004, EP-104, Engedi1000, JTA-004, CYP 004, Lorecivivint, and others
• Osteoarthritis Therapeutic Assessment: Osteoarthritis current marketed and Osteoarthritis emerging therapies
• Osteoarthritis Market Dynamics: Osteoarthritis market drivers and Osteoarthritis market barriers

Request for Sample PDF Report for Osteoarthritis Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/osteoarthritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Osteoarthritis Report Introduction
2. Osteoarthritis Executive Summary
3. Osteoarthritis Overview
4. Osteoarthritis- Analytical Perspective In-depth Commercial Assessment
5. Osteoarthritis Pipeline Therapeutics
6. Osteoarthritis Late Stage Products (Phase II/III)
7. Osteoarthritis Mid Stage Products (Phase II)
8. Osteoarthritis Early Stage Products (Phase I)
9. Osteoarthritis Preclinical Stage Products
10. Osteoarthritis Therapeutics Assessment
11. Osteoarthritis Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Osteoarthritis Key Companies
14. Osteoarthritis Key Products
15. Osteoarthritis Unmet Needs
16 . Osteoarthritis Market Drivers and Barriers
17. Osteoarthritis Future Perspectives and Conclusion
18. Osteoarthritis Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Osteoarthritis Market https://www.delveinsight.com/report-store/osteoarthritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Osteoarthritis-Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Osteoarthritis Epidemiology https://www.delveinsight.com/report-store/osteoarthritis-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Osteoarthritis Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:

Monkeypox Market https://www.delveinsight.com/report-store/monkeypox-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Monkeypox Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Monkeypox, historical and forecasted epidemiology as well as the Monkeypox market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Pars Planitis Market
https://www.delveinsight.com/report-store/pars-plantis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Pars Plantis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Pars Plantis, historical and forecasted epidemiology as well as the Pars Plantis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Patient Monitoring Devices Market
https://www.delveinsight.com/report-store/patient-monitoring-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Patient Monitoring Devices Market By Type Of Devices (Neuromonitoring Devices, Cardiac Monitoring Devices, Respiratory Monitoring Devices, Hemodynamic Monitoring Devices, Blood Glucose Monitoring Systems, And Others), By Application (Cardiology, Neurology, Respiratory, And Others), By End-User (Hospitals & Clinics, Ambulatory Surgical Centers, Home Care Settings, And Others), by geography, is anticipated to grow at a significant CAGR till 2028 owing to the growing prevalence of various chronic disorders and integration of advanced technology in the products

Typhoid Market https://www.delveinsight.com/report-store/typhoid-fever-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Typhoid Fever Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Typhoid Fever, historical and forecasted epidemiology as well as the Typhoid Fever market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Zika Virus Market https://www.delveinsight.com/report-store/zika-virus-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Zika Virus Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Zika Virus, historical and forecasted epidemiology as well as the Zika Virus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Opioid Use Disorder Market https://www.delveinsight.com/report-store/opioid-use-disorder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Opioid Use Disorder (OUD) - Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the Opioid Use Disorder (OUD), historical and forecasted epidemiology as well as the Opioid Use Disorder (OUD) market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Recent Blog's By DelveInsight:
• Insights Into The Cutaneous T-cell Lymphoma Treatment Market
https://www.delveinsight.com/blog/cutaneous-t-cell-lymphoma-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Roche's HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Emerging Role of Digital Health in the Field of Oncology
https://www.delveinsight.com/blog/digital-health-to-improve-cancer-management?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
https://www.delveinsight.com/blog/evolving-als-treatment-landscape?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How are Technological Trends and Innovations Reshaping the Dementia Care
https://www.delveinsight.com/blog/technological-innovations-in-dementia-care?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
https://www.delveinsight.com/blog/clinical-diagnostics-market-outlook?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
https://www.delveinsight.com/blog/non-opioid-analgesics-for-chronic-pain-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
https://www.delveinsight.com/blog/alpha-1-antitrypsin-deficiency-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Evaluating the Key Trends and Technologies Shaping the Future of Dentistry https://www.delveinsight.com/blog/emerging-trends-in-dental-care-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.